Adherence: latest news

Adherence resources

  • HIV and your health

    The outlook has never been better for people with HIV in the UK. With the right HIV treatment and care, most people can expect to have...

    From: Booklets

    Information level Level 2
  • Talking to your doctor

    Taking antiretroviral therapy is a long-term commitment. At present, once you start the drugs, you are likely to be on them for the rest of your life. ...

    From: Booklets

    Information level Level 2
  • Adherence tips

    You may find that a pill box, a phone alarm or a diary helps you with adherence.Adherence can be more challenging when travelling or when...

    From: Factsheets

    Information level Level 2
  • Changing HIV treatment

    Talk to your doctor if you are concerned about any side-effects you are experiencing.If you are having problems taking your HIV treatment, it’s important to be honest...

    From: Factsheets

    Information level Level 2
  • Taking your HIV treatment (adherence)

    Taking your medication exactly as prescribed is key to HIV treatment working.As treatment is a long-term commitment, it’s important that your treatment suits your lifestyle.If you find...

    From: Factsheets

    Information level Level 2
  • Drug resistance

    It's important to always take your HIV treatment at the right times and in the right amounts. If you don't, HIV may become drug resistant.When...

    From: The basics

    Information level Level 1
  • An HIV treatment journey

    This illustrated leaflet shows the journey a lot of people go on with HIV treatment. However, each person’s situation is different. Your own circumstances may...

    From: The basics

    Information level Level 1
  • Taking drugs on time

    For HIV treatment to work well, you need to always take your pills at the right time, without missing any doses.Taking anti-HIV drugs regularly will...

    From: The basics

    Information level Level 1
  • Your diet and anti-HIV drugs

    Choosing a drug combination that you can fit into your existing eating habits is usually easier than trying to adjust your eating habits to fit the drugs. There...

    From: Booklets

    Information level Level 2
  • Travelling with HIV medications – time zone changes

    Travelling to a new time zone may affect when it’s best to take your medication.If you have an undetectable viral load, taking one dose a few hours...

    From: Factsheets

    Information level Level 2
  • Why taking your HIV treatment properly is so important

    The currently available anti-HIV drugs cannot cure HIV. However, treatment with a combination of these drugs (usually three) can reduce the amount of HIV in your blood (your...

    From: Booklets

    Information level Level 2
  • What does taking your HIV treatment involve?

    Taking your drugs as prescribed is often called ‘adherence’. Adherence to your HIV treatment means: Taking all the medicines that make up your...

    From: Booklets

    Information level Level 2
  • Factors that can affect adherence

    Medicines from the three main classes of anti-HIV drugs (nucleoside reverse transcriptase inhibitors or NRTIs; non-nucleoside reverse transcriptase inhibitors or NNRTIs; and protease inhibitors) are available in forms...

    From: Booklets

    Information level Level 2
  • Taking your HIV treatment

    This booklet is a starting point for anyone who wants to know about treatment for HIV. It provides basic information about how HIV treatment works...

    From: Booklets

    Information level Level 2
  • Adherence

    Information on adherence to anti-HIV drugs, including advice on how patients can maintain adherence to their therapy and how healthcare providers can help....

    From: HIV treatments directory

    Information level Level 4

Adherence features

Adherence in your own words

Adherence news from aidsmap

More news

Adherence news selected from other sources

  • Linking HIV stigma, denial and poor health 

    People living with HIV who stigmatise and think negatively about themselves because of their HIV status are less likely to start treatment and reach viral load suppression.

    08 November 2018 | AVERT
  • How substance use affects adherence to PrEP among gay and bisexual men

    On average, club drug users were no more likely to miss a dose of PrEP than non-club drug users. However, club drug use (at the event level) increased the odds of missing a dose on the same day by 55 percent and the next day (e.g., a "carryover effect") by 60 percent. "This suggests that although club drug users appeared to have similar aggregate levels of adherence, their missed doses were specifically timed around instances of club drug use.

    24 October 2018 | Medical Xpress
  • How smartphones are becoming a weapon in the global fight against tuberculosis

    Mobile technologies devised by researchers at the University of California, San Diego, and Johns Hopkins are allowing patients to use their phones to record daily medication intake. The encrypted videos are sent to public health workers who can watch them from their cubicles, instead of traveling long distances every day to visit patients at their homes or workplaces.

    21 August 2018 | STAT
  • Should Gilead Be Worried About This New Monthly HIV Medication?

    Yesterday, Johnson & Johnson and ViiV Healthcare announced positive results from the Atlas phase 3 study testing their two-drug HIV treatment containing an investigational drug cabotegravir and rilpivirine, a nucleoside reverse transcriptase inhibitor (NRTI) sold by Johnson & Johnson as Edurant. The important thing here isn't going from three medications to two, but that ViiV and Johnson & Johnson's cabotegravir and rilpivirine combination is injected once a month compared to a daily therapy for the three-drug combination.

    16 August 2018 | Motley Fool
  • HIV drug research in Wales to cut infection risk

    Nearly 400 people have been taking part in a three-year trial of the drugs in Wales since last summer. Cardiff University will now examine how people have been taking the medicine - and if that affects the protection.

    16 August 2018 | BBC
  • TAC: ARV treatment education best way to bring down HIV infection rates

    An activist organisation, the Treatment Action Campaign (TAC), says that for South Africa to further decrease the rate of new HIV infections more needs to be done to curb treatment defaulting for persons on the ARV treatment programme.

    18 July 2018 | Eyewitness News
  • Blood, Hair, or Urine? Weighing PrEP Adherence Options Beyond Self-Report

    Understanding whether a person with a PrEP prescription is actually using the medication is something a provider may want to know. Currently, a few measures determine adherence to PrEP: self-report, hair, dried blood spot, and urine analysis. As of now, no one guideline or definitive standard is being used. Clinicians and researchers presented their recent findings at the 13th Annual Adherence Conference last month in Miami.

    16 July 2018 | The Body Pro
  • 'Emotional closeness’ key to successful HIV treatment support

    The type of relationship someone living with HIV has with both their social network and a nominated ‘treatment partner’ is likely to influence whether they are virally suppressed, research from Botswana suggests.

    15 June 2018 | AVERT
  • Is the World Ready for Long-Acting HIV Treatment?

    "As we look at this question [of] where do long-acting antiretrovirals fit into the armamentarium," commented Carl Dieffenbach, the director of the Division of AIDS within the National Institute of Allergy and Infectious Diseases, "we have to ask ourselves the question: What problems are long-acting or sustained-release formulations solving, and what problems or concerns are the introduction of these type of formulations actually creating?"

    11 June 2018 | The Body Pro
  • Short Cycle ART Noninferior to Continuous Therapy in Youth With HIV

    Short cycle therapy (SCT) comprising an antiretroviral therapy (ART) regime of 5 days on and 2 off achieved sustainable noninferiority of virological suppression in young people with HIV compared with continuous therapy (CT) over a median of 3.6 years, according to research published in PLos One.

    25 May 2018 | Infectious Disease Advisor
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.